Skip to main content
Premium Trial:

Request an Annual Quote

ABI to Sell Mass Spec Manufacturing Facility to Delphi Medical Systems

NEW YORK, June 9 (GenomeWeb News) - In another step of its ongoing reorganization, Applied Biosystems is selling its Texas-based mass spectrometry manufacturing facility to Delphi Medical Systems, a multi-faceted instrument manufacturer, according to people familiar with the transaction.

 

The deal, which was to have closed on June 6, will be announced June 9, according to one of these individuals.

 

Based in Stafford, on the outskirts of Houston, ABI's facility employs around 50 people. The 50,000-square-foot facility manufactures mass specs and related software, protein sequencers, peptide- and DNA-synthesis products, and cell-detection instruments, she said.

 

Financial terms of the deal or the status of the employees were not immediately known.

 

A spokesperson for ABI confirmed the sale, but did not elaborate. She referred a GenomeWeb News reporter to a second spokesperson, who did not immediately return a telephone call seeking comment.

The sale of the facility is consistent with an ongoing restructuring at ABI, especially in its proteomic instrument business. Last September, the company transferred its Voyager MALDI-TOF and 4700 MALDI-TOF/TOF instruments, made in Houston, to its joint venture with MDS. The joint venture already produces a number of mass spectrometers sold by ABI, which will continue to market, sell, and service the systems.

R&D and manufacturing of the Voyager and 4700 mass spectrometers --- the only ones that ABI manufactured in-house at the time --- and related intellectual property will be moved to the ABI/MDS Sciex Instruments joint venture in Toronto.

As part of that deal, manufacturing will move from ABI's facility to MDS Sciex. In addition, ABI has reduced its MALDI R&D group in Framingham, Mass., by an undisclosed number of people and will transfer the remainder of the group to Toronto. All future MALDI-TOF-based mass spec systems will be developed in Toronto.
 
Delphi Medical Systems, based in
Troy, Mich., manufactures instruments for dialysis, infusion, in vitro diagnostics, respiratory care, and equipment for monitoring vital signs, according to its web site.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.